Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab

Istituto Clinico Humanitas85 enrolled

Overview

The primary objective is to identify molecular features predicting response or resistance to cetuximab

Secondary objective is to investigate association of genomic status of EGFR and HER-2 genes with clinical outcome, including objective response, time to progression and survival

Study Type

OBSERVATIONAL

Enrollment

Conditions

Colorectal Neoplasms

Interventions

Gene mutations analysis and FISHGENETIC

FISH and mutation analysis of multiple genes

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed diagnosis of colorectal cancer with available tumor tissue and clinical data; presence of at least one measurable lesion. Exclusion Criteria: * Less than 3 weeks after completion of previous radiotherapy

Locations (1)

Istituto Clinico Humanitas

Rozzano, Milan, Italy

Outcomes

Primary Outcomes

Association of different biomarkers with Cetuximab sensitivity

Time frame: Assessment every two months

Secondary Outcomes

Association of different biomarkers with time to progression and survival

Time frame: At the end of the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.